$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
阿昔替尼(Axitinib)的副作用和不良反应
2025-10-19 11:44:20
Check Details
阿地白介素(Proleukin)原研药现在可以在哪买到
2025-10-19 11:44:20
Check Details
卡博替尼(Cabozantinib)的用法用量:常用剂量、剂量调整
2025-10-19 11:44:20
Check Details
FDA批准卡博替尼(Cabometyx)用于既往接受过治疗的晚期神经内分泌肿瘤患者
2025-10-19 11:44:20
Check Details
甲状腺癌的常见类型
2025-10-19 11:44:20
Check Details
乐伐替尼治疗转移性分化型甲状腺癌
2025-10-19 11:44:20
Check Details
发现早治疗及时,甲状腺癌的五年存活率可达80%以上
2025-10-19 11:44:20
Check Details
甲状腺癌五大分类
2025-10-19 11:44:20
Check Details
卡博替尼治疗甲状腺髓样癌的临床评价
2025-10-19 11:44:20
Check Details
甲状腺肿大与甲状腺癌的区别
2025-10-19 11:44:20
Check Details
卡博替尼治疗碘难治分化型甲状腺癌研究
2025-10-19 11:44:20
Check Details
甲状腺癌的早期症状有哪些?
2025-10-19 11:44:20
Check Details
1
2
...
2432
2433
2434
2435
2436
2437
2438
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Chemical Structure of Capivasertib: A Novel AKT Inhibitor
2
Capivasertib: An AKT Inhibitor for Breast and Prostate Cancer
3
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
4
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
5
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
6
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
7
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
8
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
9
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
10
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
11
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
12
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer